[go: up one dir, main page]

PL1989214T3 - Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów - Google Patents

Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów

Info

Publication number
PL1989214T3
PL1989214T3 PL07763545T PL07763545T PL1989214T3 PL 1989214 T3 PL1989214 T3 PL 1989214T3 PL 07763545 T PL07763545 T PL 07763545T PL 07763545 T PL07763545 T PL 07763545T PL 1989214 T3 PL1989214 T3 PL 1989214T3
Authority
PL
Poland
Prior art keywords
polymorphs
preparing
receptor agonist
adenosine receptor
adenosine
Prior art date
Application number
PL07763545T
Other languages
English (en)
Inventor
Jeff Zablocki
Elfatih Elzein
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1989214(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL1989214T3 publication Critical patent/PL1989214T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL07763545T 2006-02-03 2007-02-02 Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów PL1989214T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76511406P 2006-02-03 2006-02-03
US80185706P 2006-05-18 2006-05-18
EP07763545.6A EP1989214B8 (en) 2006-02-03 2007-02-02 Process for preparing an a2a-adenosine receptor agonist and its polymorphs

Publications (1)

Publication Number Publication Date
PL1989214T3 true PL1989214T3 (pl) 2017-07-31

Family

ID=38120353

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07763545T PL1989214T3 (pl) 2006-02-03 2007-02-02 Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów

Country Status (17)

Country Link
US (8) US7732595B2 (pl)
EP (2) EP1989214B8 (pl)
JP (3) JP5326156B2 (pl)
KR (2) KR101494125B1 (pl)
CN (1) CN102260311A (pl)
AU (1) AU2007212542B2 (pl)
CA (1) CA2640089C (pl)
ES (1) ES2593028T3 (pl)
IL (2) IL193153A (pl)
MX (1) MX2010014060A (pl)
NO (1) NO341322B1 (pl)
NZ (1) NZ570239A (pl)
PL (1) PL1989214T3 (pl)
PT (1) PT1989214T (pl)
RU (1) RU2447081C2 (pl)
SI (1) SI1989214T1 (pl)
WO (1) WO2007092372A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
RU2007114908A (ru) * 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
EP2066232A1 (en) * 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
NZ580940A (en) * 2007-05-17 2012-02-24 Gilead Palo Alto Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs
EP2225255A4 (en) * 2007-12-20 2011-07-20 King Pharmaceuticals Res & Dev CRYSTALLINE FORMS OF 2- [2- (4-CHLOROPHENYL) ETHOXY] ADENOSINE
CA2716501A1 (en) * 2008-02-29 2009-09-03 King Pharmaceuticals Research And Development, Inc. Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine
AU2009256009B2 (en) * 2008-06-06 2014-02-06 Neurmedix, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
WO2012149196A1 (en) 2011-04-27 2012-11-01 Reliable Biopharmaceutical Corporation Improved processes for the preparation of regadenoson and a new crystalline form thereof
CZ308577B6 (cs) * 2011-08-18 2020-12-16 Farmak, A. S. Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
WO2014063134A1 (en) 2012-10-19 2014-04-24 New York University Methods for inhibiting osteolysis
EP3760637A3 (en) 2013-04-11 2021-04-07 AMRI Italy S.r.l. Stable solid forms of regadenoson
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
US9624258B2 (en) * 2013-05-30 2017-04-18 Biophore India Pharmaceuticals Pvt. Ltd. Polymorph of regadenoson
NZ720106A (en) * 2013-12-10 2017-02-24 Scinopharm Taiwan Ltd A process for the preparation of regadenoson
CN105085593A (zh) * 2014-04-21 2015-11-25 上海紫源制药有限公司 瑞加德松的晶型及其制备方法
CN105198950B (zh) * 2014-06-17 2018-10-02 上海紫源制药有限公司 一种瑞加德松晶型e的制备方法
CN105175468B (zh) * 2014-06-17 2018-06-19 上海紫源制药有限公司 一种瑞加德松晶型b的制备方法
US10442832B2 (en) 2015-02-06 2019-10-15 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
US9809617B2 (en) 2015-07-03 2017-11-07 Shanghai Ziyuan Pharmaceutical Co., Ltd. Crystal form of regadenoson and preparation method thereof
CN106397442B (zh) * 2015-07-28 2020-03-27 国药集团国瑞药业有限公司 一种瑞加德松的纯化方法
US10392417B2 (en) 2016-11-04 2019-08-27 Apicore Us Llc Polymorph of regadenoson and process for preparation thereof
CN106749254B (zh) * 2017-01-10 2018-05-25 青岛科技大学 一种6-氨基嘌呤乙基萘乙酸酯类化合物及其作为植物生长调节剂的用途
WO2019191389A1 (en) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Solid-state forms of regadenoson, their use and preparation
US10815265B2 (en) 2018-06-29 2020-10-27 Usv Private Limited Process for preparation of regadenoson and polymorphs thereof
CN117430647A (zh) * 2023-11-02 2024-01-23 康普药业股份有限公司 一种瑞加诺生的制备方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4826038Y1 (pl) 1970-12-25 1973-07-30
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4990498A (en) 1988-04-26 1991-02-05 Temple University-Of The Commonwealth System Of Higher Education 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
WO1990005526A1 (fr) * 1988-11-15 1990-05-31 Yamasa Shoyu Kabushiki Kaisha Agent de traitement et de prophylaxie des troubles ischemiques du c×ur ou du cerveau
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DE69022176T2 (de) * 1989-06-20 1996-02-15 Toa Eiyo Ltd., Tokio/Tokyo Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat.
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) * 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
JPH08500967A (ja) 1992-06-12 1996-02-06 ガーヴァン インスティチュート オブ メディカル リサーチ ヒトＡ１，Ａ２ａおよびＡ２ｂアデノシン受容体をエンコードするＤＮＡ配列
EP0601322A3 (en) * 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5477857A (en) 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
WO1995023148A1 (en) * 1994-02-23 1995-08-31 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) * 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
CA2295195C (en) 1997-06-18 2009-12-15 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
EP1011608A4 (en) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HEART AND NEUTRAL FAILURE OR DAMAGE RELATED TO ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR CALLED BY THE ADDITION OF SPECIFIC MEDICINES
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
NZ517546A (en) 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6758388B1 (en) 2001-02-27 2004-07-06 Rohr, Inc. Titanium aluminide honeycomb panel structures and fabrication method for the same
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
CN1268610C (zh) * 2001-05-14 2006-08-09 诺瓦提斯公司 磺酰胺衍生物
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PL370207A1 (pl) * 2001-11-09 2005-05-16 Cv Therapeutics, Inc. Antagoniści receptora A2B adenozyny
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002366811B2 (en) * 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
CA2482928A1 (en) 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
AU2004316372B2 (en) 2004-01-27 2011-05-12 Gilead Sciences, Inc. Myocardial perfusion imaging using adenosine receptor agonists
US20060159627A1 (en) * 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
RU2007114908A (ru) * 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
WO2006076698A1 (en) * 2005-01-12 2006-07-20 King Pharmaceuticals Reserch & Development, Inc. Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
US20070114269A1 (en) 2005-11-22 2007-05-24 Straza George C Formed metal core sandwich structure and method and system for making same
CA2640089C (en) * 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010502649A (ja) 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
EP2066232A1 (en) * 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
NZ580940A (en) 2007-05-17 2012-02-24 Gilead Palo Alto Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20100272711A1 (en) 2007-12-12 2010-10-28 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
WO2014068589A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
US9624258B2 (en) * 2013-05-30 2017-04-18 Biophore India Pharmaceuticals Pvt. Ltd. Polymorph of regadenoson
NZ720106A (en) * 2013-12-10 2017-02-24 Scinopharm Taiwan Ltd A process for the preparation of regadenoson

Also Published As

Publication number Publication date
NO341322B1 (no) 2017-10-09
USRE47301E1 (en) 2019-03-19
US7956179B2 (en) 2011-06-07
US20070265445A1 (en) 2007-11-15
NO20083395L (no) 2008-08-01
JP5326156B2 (ja) 2013-10-30
US20070225247A1 (en) 2007-09-27
JP2009525347A (ja) 2009-07-09
US20100267953A1 (en) 2010-10-21
NZ570239A (en) 2011-09-30
EP2581381A3 (en) 2013-10-30
PT1989214T (pt) 2016-09-22
EP1989214B8 (en) 2016-12-21
US8524883B2 (en) 2013-09-03
KR101494125B1 (ko) 2015-02-16
JP2013010791A (ja) 2013-01-17
IL252700A0 (en) 2017-08-31
ES2593028T3 (es) 2016-12-05
US9085601B2 (en) 2015-07-21
IL193153A0 (en) 2009-02-11
RU2447081C2 (ru) 2012-04-10
AU2007212542B2 (en) 2013-01-31
SI1989214T1 (sl) 2016-10-28
JP2013014620A (ja) 2013-01-24
US20110257387A1 (en) 2011-10-20
US7732595B2 (en) 2010-06-08
US8106183B2 (en) 2012-01-31
AU2007212542A1 (en) 2007-08-16
US20120165350A1 (en) 2012-06-28
KR20130130868A (ko) 2013-12-02
HK1127358A1 (zh) 2009-09-25
RU2008131956A (ru) 2010-02-10
CN102260311A (zh) 2011-11-30
CA2640089C (en) 2013-07-23
US7671192B2 (en) 2010-03-02
KR20080090491A (ko) 2008-10-08
WO2007092372A1 (en) 2007-08-16
US20140213539A1 (en) 2014-07-31
US20100179313A1 (en) 2010-07-15
CA2640089A1 (en) 2007-08-16
EP1989214A1 (en) 2008-11-12
MX2010014060A (es) 2011-01-18
US8268988B2 (en) 2012-09-18
EP2581381A2 (en) 2013-04-17
IL193153A (en) 2017-06-29
EP1989214B1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
IL252700A0 (en) A process for preparing an adenosine a2a receptor agonist and its polymorphs
IL201856A0 (en) Process for preparing an a2a-adenosine receptor agonist and its polymorphs
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
IL192573A0 (en) Process for preparing substituted biphenyls
GB0607196D0 (en) G-protein coupled receptor agonists
EP2170072A4 (en) Farnesoid X RECEPTOR AGONISTS
ZA201003439B (en) Novel glucocorticoid receptor agonists
IL198117A0 (en) Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
EP2222314A4 (en) METHOD AND MEANS FOR OBTAINING BRONCHORELAXATION
PL2213654T3 (pl) Sposób wytwarzania pochodnych 2-amino-5-bromobenzamidu
EP2019118A4 (en) METHOD FOR SYNTHETIZING THYMOSINS
ZA200806666B (en) Process for preparing an A2A-adenosine receptor agonist and its polymorphs
IL184342A0 (en) Process for preparing ??-amino-??-hydroxycarboxamides
GB2436466B (en) Feeder apparatus
GB2456999B (en) Method for preparing 2-deoxy-L-ribose
EP2101618A4 (en) APPARATUS FOR RETAINING SUBSTANTIALLY CYLINDRICALLY SHAPED ELEMENTS
ZA201000397B (en) Process for preparing oxazolidine-and oxazolidinone-aminodiols and related intermediates
ZA200805781B (en) Process for preparing substituted biphenyls
IL200389A0 (en) Process for preparing substituted phenylhydrazines
IL195262A0 (en) Process for preparing hydroxylpatite
GB0700770D0 (en) Apparatus for detecting retinal neuropathy
EP2339030A4 (en) SCREENING PROCESS FOR LIVER X RECEPTOR AGONISTS AND APPLICATION THEREOF
EG26107A (en) Way to prepare medicine Alandral
GB0607351D0 (en) Apparatus for breathalysing
EP2367804A4 (en) METHOD FOR PRODUCING AN EFAVIRENZ POLYMORPHS